Gelderse Vallei Hospital   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Ede Netherlands

Organization Overview

First Clinical Trial
2012
NCT01362959
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Arthur van Zanten | Gelderse Vallei Hospital | Intensive Care Research Foundation, Gelderse Vallei Hospital

Active Ingredients

Drugs in Phase 4 Trials (4)

clopidogrel (plavix) (1 trial)

nicotine (nicorette) (1 trial)

prasugrel (effient) (1 trial)

ticagrelor (brilinta) (1 trial)

Drugs in Phase 2 Trials (2)

thiamine (1 trial)

vitamin c (2 trials)

Drugs in Other Trials (2)

collagen (1 trial)

maltodextrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Angina, Unstable (Phase 4)

Delirium (Phase 4)

Heart Arrest (Phase 2)

Infarction (Phase 4)

Myocardial Infarction (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

Psychomotor Agitation (Phase 4)

Substance Withdrawal Syndrome (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8